Announcements, milestones and insights from across the Syngenis platform and laboratories.
A simple, filterable feed of company news and longer perspective pieces. Each article has its own indexable URL, a clear date, an author, a category and a share image.
Milestones, partnerships and facility updates.
Perspectives on RNA medicine, AI discovery and sovereign capability.
The first candidate designed end to end by Syngenis One has entered laboratory validation, completing the full discovery to laboratory workflow for the first time.
Human grade DNA and RNA manufacturing is concentrated in a small number of countries. Syngenis is bringing that capability onshore, with Australia's only commercial RNA facility.
For a century, medicine was built from chemistry. RNA and DNA medicines work differently, reading, understanding and responding to disease at the molecular level.
Get milestones, announcements and perspectives from Syngenis as they are published.
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
AI led therapeutic programs and an aptamer based diagnostics pipeline.
A specialist nucleic acid CRO with in silico trial modelling.
Consumer genomics at a mass market price.
Infrastructure that channels research investment into the pipeline.